MedTrace Logo

Zimberelimab Plus Metformin for Recurrent Ovarian Clear Cell Carcinoma

NCT05759312 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2023-03-08

No results posted yet for this study

Summary

This study aims to evaluate the safety and effectiveness of zimberelimab combined with metformin in treating relapsed/persistent ovarian clear cell carcinoma.

Conditions

Interventions

DRUG

Zimberelimab

Zimberelimab 240mg IV every 2 weeks

DRUG

Metformin Hydrochloride

Metformin 2000mg PO QD

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Principal Investigators

  • Libing Xiang · Department of Gynecologic Oncology, Zhongshan Hospital, Fudan University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-31
Primary Completion
2025-02-28
Completion
2025-02-28

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05759312 on ClinicalTrials.gov